GRAd-COV2, a gorilla adenovirus-based candidate vaccine against COVID-19, is safe and immunogenic in younger and older adults

Originally published on Sci Transl Med. 2021 Oct 26. doi: 10.1126/scitranslmed. abj1996.

Read the full paper
Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19News, Publications
Strong immunogenicity of heterologous prime-boost immunizations with the experimental vaccine GRAd-COV2 and BNT162b2 or ChAdOx1-nCOV19News, Publications